Efficacy and Safety of Liposomal Bupivacaine in Thoracic Paravertebral Nerve Block

Launched by YONGTAO SUN · Dec 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to manage pain after surgery, specifically looking at a treatment called liposomal bupivacaine used in a method known as thoracic paravertebral nerve block. This approach aims to help patients feel less pain after undergoing a procedure called thoracoscopic lobectomy, which involves removing a part of the lung. The trial will also assess how effective this treatment is compared to standard pain management techniques and whether it is safe for patients.

To participate in the trial, individuals need to be at least 18 years old and scheduled for their first thoracoscopic lobectomy under general anesthesia. They should be in generally good health, as defined by certain medical guidelines. However, individuals who are pregnant, have specific health issues, or are using certain medications may not be eligible. Participants in the trial will receive either the new treatment or the standard care, and they will be closely monitored for any side effects or pain relief during their recovery. This study is not yet recruiting, but it represents a hopeful step toward improving postoperative pain management for lung surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Age ≥18 years old;
• • 2) Patients undergoing unilateral initial thoracoscopic lobectomy under general anesthesia (TV or robot-assisted);
• • 3) American Society of Anesthesiologists (ASA) Grade I - III;
• • 4) Voluntarily participate in the study and sign the informed consent.
• Exclusion Criteria:
• • 1) Pregnant or lactating women;
• • 2) Pulmonary wedge-shaped resection;
• • 3) ≥2 thoracic drainage tubes;
• • 4) Abnormal liver function: ALT and/or AST\>2×ULN, or
• • TBIL≥1.5×ULN;
• • 5) Renal function impairment (serum creatinine \>176μmol/L), or received dialysis treatment within 28 days before surgery;
• • 6) Participate in another research trial involving an investigational drug within 6 months;
• • 7) A history of drug or alcohol abuse;
• • 8) Long-term use of opioids (more than 3 months or more than 5 mg daily morphine equivalent per day for 1 month);
• • 9) History of allergy to local anesthetics or one of the investigational drugs;
• • 10) Uncontrolled mental or neurological symptoms.